We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-15.48%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$504M
AUM Growth
-$158M
Cap. Flow
-$56.6M
Cap. Flow %
-11.24%
Top 10 Hldgs %
27.49%
Holding
102
New
6
Increased
45
Reduced
33
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$10M
2
ALKS icon
Alkermes
ALKS
+$9.75M
3
ENDP
Endo International plc
ENDP
+$6.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.86M
5
GILD icon
Gilead Sciences
GILD
+$5.05M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$11.5M
2
MDT icon
Medtronic
MDT
+$8.44M
3
HNT
HEALTH NET INC
HNT
+$8.35M
4
ABMD
Abiomed Inc
ABMD
+$8.02M
5
CVS icon
CVS Health
CVS
+$7.29M

Sector Composition

Rank Sector Weight
1 Healthcare 93.13%
2 Financials 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDX icon
51
Becton Dickinson
BDX
$48.2B
$3.8M 0.75%
25,625
-45,100
-64% -$6.4M
LIVN icon
52
LivaNova
LIVN
$4.2B
$3.78M 0.75%
70,000
+4,000
+6% +$222K
ELGX
53
DELISTED
Endologix Inc
ELGX
$3.64M 0.72%
43,500
+1,500
+4% +$124K
HZNP
54
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.31M 0.66%
200,000
+54,000
+37% +$945K
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$3.3M 0.66%
+105,000
New +$3.63M
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.2M 0.63%
115,000
-11,000
-9% -$367K
HTWR
57
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$3.14M 0.62%
100,000
+33,000
+49% +$1.12M
OMCL icon
58
Omnicell
OMCL
$1.68B
$3.07M 0.61%
110,000
+36,000
+49% +$989K
IOVA icon
59
Iovance Biotherapeutics
IOVA
$2.87B
$3.05M 0.61%
600,000
+25,000
+4% +$137K
CEMP
60
DELISTED
Cempra, Inc.
CEMP
$3M 0.59%
171,000
-55,000
-24% -$997K
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.97M 0.59%
170,000
-3,000
-2% -$61.1K
DVAX
62
DELISTED
Dynavax Technologies
DVAX
$2.89M 0.57%
150,000
+95,000
+173% +$1.92M
PODD icon
63
Insulet
PODD
$9.79B
$2.72M 0.54%
82,000
-14,000
-15% -$440K
XNCR icon
64
Xencor
XNCR
$1.55B
$2.68M 0.53%
200,000
+18,697
+10% +$221K
EXEL icon
65
Exelixis
EXEL
$13.4B
$2.6M 0.52%
650,000
+190,000
+41% +$804K
IONS icon
66
Ionis Pharmaceuticals
IONS
$9.4B
$2.59M 0.51%
64,000
-3,000
-4% -$122K
CMRX
67
DELISTED
Chimerix, Inc.
CMRX
$2.56M 0.51%
500,000
+244,000
+95% +$1.59M
ESPR
68
DELISTED
Esperion Therapeutics
ESPR
$2.54M 0.5%
150,000
+50,000
+50% +$804K
RARE icon
69
Ultragenyx Pharmaceutical
RARE
$2.55B
$2.53M 0.5%
+40,000
New +$2.62M
KYNB
70
Kyntra Bio
KYNB
$29.4M
$2.43M 0.48%
4,560
+2,560
+128% +$1.28M
NBIX icon
71
Neurocrine Biosciences
NBIX
$16.6B
$2.37M 0.47%
+60,000
New +$2.38M
MGNX icon
72
MacroGenics
MGNX
$257M
$2.25M 0.45%
120,000
+26,000
+28% +$495K
PTLA
73
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.14M 0.43%
105,000
+43,000
+69% +$1.36M
PCRX icon
74
Pacira BioSciences
PCRX
$997M
$2.12M 0.42%
40,000
+5,000
+14% +$292K
HOLX
75
DELISTED
Hologic
HOLX
$2.07M 0.41%
60,000
+26,699
+80% +$931K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2016 Portfolio in Review

As of Q1 2016, Rhenman & Partners Asset Management held 102 positions worth $504M, down 24% from $661M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $56.6M in Q1 2016, closing 10 positions and reducing 33 holdings. Its most notable exit was HEALTH NET INC, an estimated $8.35M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Biogen worth $9.89M.

  • Rhenman & Partners Asset Management's largest Q1 2016 buy was Biogen: 38,000 shares worth $9.89M.
  • Rhenman & Partners Asset Management added most to Alkermes in Q1 2016, an estimated $9.75M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2016 reduction was Perrigo, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited HEALTH NET INC in Q1 2016, selling an estimated $8.35M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $504M portfolio in Q1 2016.
  • Rhenman & Partners Asset Management opened 6 new positions and closed 10 in Q1 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 24% quarter-over-quarter to $504M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2016, filed 19 Apr 2016.